共 50 条
- [41] A phase 1b study of sotorasib, a specific and irreversible KRASG12C inhibitor, in combination with other anticancer therapies in advanced colorectal cancer (CRC) and other solid tumors (CodeBreaK 101)JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)Hong, David S.Yaeger, RonaKuboki, YasutoshiMasuishi, ToshikiBarve, Minal A.Falchook, Gerald StevenGovindan, RamaswamySohal, DavendraKasi, Pashtoon MurtazaBurns, Timothy F.Langer, Corey J.Puri, SonamChan, EmilyJafarinasabian, PegahNgarmchamnanrith, GatareeRehn, MarkoTran, QuiGandara, David R.Strickler, John H.Fakih, Marwan
- [43] KRASG12C Inhibitor as a Treatment Option for Non-Small-Cell Lung Cancer with Comorbid Interstitial PneumoniaCANCERS, 2024, 16 (07)Fujimoto, KazushiIkeda, SatoshiTabata, ErinaKaneko, TaichiSagawa, ShinobuYamada, ChieriKumagai, KosumiFukushima, TakashiHaga, SanshiroWatanabe, MasayukiMuraoka, TatsuyaSekine, AkimasaBaba, TomohisaOgura, Takashi
- [44] Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancerNature Communications, 14Irati MacayaMarta RomanConnor WelchRodrigo Entrialgo-CadiernoMarina SalmonAlba SantosIker FeliuJoanna KovalskiInes LopezMaria Rodriguez-RemirezSara Palomino-EcheverriaShane M. LonfgrenMacarena FerreroSilvia CalabuigIziar A. LudwigDavid Lara-AstiasoEloisa Jantus-LewintreElizabeth GuruceagaShruthi NarayananMariano Ponz-SarviseAntonio Pineda-LucenaFernando LecandaDavide RuggeroPurvesh KhatriEnrique SantamariaJoaquin Fernandez-IrigoyenIrene FerrerLuis Paz-AresMatthias DrostenMariano BarbacidIgnacio Gil-BazoSilve Vicent
- [45] A phase 1b study evaluating the safety and efficacy of sotorasib, a KRASG12C inhibitor, in combination with trametinib, a MEK inhibitor, in KRAS p.G12C-Mutated Solid TumorsMOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)Ramalingam, SureshFakih, MarwanStrickler, JohnGovindan, RamaswamyLi, Bob T.Goldberg, SarahGandara, DavidBurns, TimothyBarve, MinalShu, CatherineFrank, RichardSohal, DavendraJafarinasabian, PegahDai, TianMather, OmarHong, David
- [46] Sotorasib-induced liver and non-liver toxicity associated with sequential sotorasib following anti-PD(L)1 in KRASG12C mutant lung cancerANNALS OF ONCOLOGY, 2022, 33 : S49 - S50Chour, A.Denis, J.Lafitte, C.Mascaux, C.Zysman, M.Lemaitre, A.Swalduz, A.Gounant, V.Cortot, A.Darrason, M.Cadranel, J.Auclin, E.Basse, C.Tissot, C.Decroisette, C.Bombaron, P.Giroux-Leprieur, E.Falchero, L.Lebosse, F.Duruisseaux, M.
- [47] Efficacy and toxicity of drugs targeting KRASG12C mutation in non-small cell lung cancer: a meta-analysisEXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (12) : 1295 - 1303Luo, WeiZhu, JingZhang, WenxueYu, AiruZhou, WeiXu, Ke
- [48] NT219, a dual inhibitor of IRS1/2 and STAT3, suppresses cancer stem cell mediated resistance to KRASG12C and KRASG12D inhibitors in solid tumorsCANCER RESEARCH, 2024, 84 (06)Reuveni, HadasAl-Hallak, Mohammed NajeebMotorwala, SarahBeal, ElizaKim, SteveBeydoun, RaficDyson, GergoryEl-Rayes, BasselChen, HerbertPhilip, A. PhilipShields, Anthony F.Pasche, BorisSigalov, KatyBen-David, HavaMiron, DaphnaAzmi, Asfar S.
- [49] Comparison Between Sotorasib with Docetaxel for the Treatment of Chinese Patients with Previously Treated NSCLC with KRASG12C Mutation: A Cost-Effectiveness Analysis to Inform Drug PricingADVANCES IN THERAPY, 2024, 41 (08) : 3159 - 3172Yi, LidanZeng, XiaohuiZhou, ZhenLiu, Qiao
- [50] Cost-effectiveness analysis of sotorasib as second-line treatment for patients with KRASG12C mutated metastatic non-small cell lung cancer (mNSCLC) in SwitzerlandSWISS MEDICAL WEEKLY, 2023, 153 : 56S - 56SEl Saadany, T.Lupatsch, J.Mark, M.Mehra, T.Schwenkglenks, M.von Moos, R.